TRACON Pharmaceuticals, Inc. (NASDAQ:TCON – Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 166,100 shares, a growth of 39.6% from the May 31st total of 119,000 shares. Based on an average daily trading volume, of 220,600 shares, the days-to-cover ratio is currently 0.8 days. Currently, 6.6% of the company’s shares are short sold.
TRACON Pharmaceuticals Stock Performance
NASDAQ:TCON opened at $1.60 on Monday. The company has a market cap of $4.29 million, a PE ratio of 0.46 and a beta of 1.28. TRACON Pharmaceuticals has a 52-week low of $0.66 and a 52-week high of $14.75. The stock has a 50-day simple moving average of $1.50 and a 200 day simple moving average of $3.42.
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.13). The company had revenue of $0.10 million during the quarter. During the same quarter in the prior year, the firm earned ($7.20) earnings per share. On average, research analysts predict that TRACON Pharmaceuticals will post -4 earnings per share for the current fiscal year.
TRACON Pharmaceuticals Dividend Announcement
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the company. StockNews.com lowered TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. HC Wainwright lowered their price target on TRACON Pharmaceuticals from $120.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd.
Get Our Latest Stock Analysis on TCON
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Recommended Stories
- Five stocks we like better than TRACON Pharmaceuticals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Recent Stock Buybacks: Adobe, Marathon, and FedEx Lead the Way
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Stocks Upgraded by Analysts: Home Depot, U.S. Steel, Alcoa
- How to Invest in Small Cap StocksĀ
- NVIDIA and TSM Stock: Is Semiconductor Sector Momentum Slowing?
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.